<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00512759</url>
  </required_header>
  <id_info>
    <org_study_id>GALACTIC</org_study_id>
    <nct_id>NCT00512759</nct_id>
  </id_info>
  <brief_title>Goal-directed Afterload Reduction in Acute Congestive Cardiac Decompensation Study</brief_title>
  <acronym>GALACTIC</acronym>
  <official_title>Goal-Directed Afterload Reduction in Acute Congestive Cardiac Decompensation Study (GALACTIC)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Basel, Switzerland</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Basel, Switzerland</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether an early goal-directed decrement of preload&#xD;
      and afterload with a target systolic blood pressure of 90-110 mmHg by aggressive&#xD;
      vasodilatation in patients with acute HF in the non-ICU setting is safe, and leads to a&#xD;
      better clinical and economical outcome&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Background: Heart failure (HF) is a chronic and progressive illness resulting from a variety&#xD;
      of cardiac causes, including ischemic and valvular heart disease, dilatative cardiomyopathy&#xD;
      or hypertension. HF may also develop suddenly, particularly as a complication of acute&#xD;
      myocardial infarction or as an acute exacerbation in patients with previously compensated&#xD;
      chronic HF. Acute HF requires immediate treatment that centers on reducing myocardial oxygen&#xD;
      demand and augmenting forward blood flow by removal of excess fluid with diuretics and&#xD;
      reduction of preload and afterload with vasodilatators. The aging of our population and the&#xD;
      higher number of patients surviving acute myocardial infarctions have lead to a dramatic&#xD;
      increase in the incidence and prevalence of HF, and obviously also on total cost burden of&#xD;
      the disease. For multiple reasons including need for restrictive use of the limited number of&#xD;
      ICU hospital beds the vast majority of elderly patients with acute HF are treated in a&#xD;
      non-ICU setting. Unfortunately, the optimal treatment of acute HF in the non-ICU setting is&#xD;
      not well defined. Pathophysiological considerations and preliminary data from the ICU setting&#xD;
      suggest that aggressive venous and arterial vasodilation may improve short and long-term&#xD;
      outcome.&#xD;
&#xD;
      Aim: To test the hypotheses that:&#xD;
&#xD;
      • An early goal-directed decrement of preload and afterload with a target systolic blood&#xD;
      pressure of 90-110 mmHg by aggressive vasodilatation in patients with acute HF in the non-ICU&#xD;
      setting is safe, and leads to a better clinical and economical outcome&#xD;
&#xD;
      Methods:&#xD;
&#xD;
      Design: Prospective, randomized, controlled, open label, interventional study Setting:&#xD;
      University Hospital Basel Patients: Patients with acute HF not requiring ICU admission&#xD;
&#xD;
      Patients admitted to the emergency department with acute HF will be randomized to:&#xD;
&#xD;
        -  Early goal-directed preload and afterload decrement using a fixed therapy schedule&#xD;
           including sublingual and transdermal nitrates, and hydralazine, followed by rapid&#xD;
           up-titration of ACE-inhibitors or AT-receptor blockers to achieve maximal vasodilatation&#xD;
           with a target systolic blood pressure of 90-110 mmHg. All other elements of treatment&#xD;
           will be according to the current guidelines of the European Society of Cardiology (ESC)&#xD;
&#xD;
        -  Standard treatment of acute HF according to the current guidelines of the ESC.&#xD;
&#xD;
      Clinical Significance: Despite the clinical and economical importance of acute HF, the&#xD;
      optimal treatment of acute HF is ill-defined. We strongly believe that our novel therapeutic&#xD;
      strategy will significantly reduce morbidity, length of hospitalisation, and possibly&#xD;
      mortality of affected patients. This would represent a first major step for an evidence-based&#xD;
      management of this common condition. Documenting medical and economic benefit of a simple,&#xD;
      safe, and inexpensive medical therapy in a randomised controlled clinical trial would provide&#xD;
      evidence-based care for the majority of patients presenting with acute HF worldwide. All&#xD;
      drugs applied in our strategy are off-patent and therefore relatively low-cost. Successful&#xD;
      implication of our treatment algorithm has the potential to significantly reduce treatment&#xD;
      costs.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 10, 2007</start_date>
  <completion_date type="Actual">February 21, 2019</completion_date>
  <primary_completion_date type="Actual">August 24, 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Death or re-hospitalization from HF</measure>
    <time_frame>180 days</time_frame>
    <description>Death or re-hospitalization due to heart failure at 180 days</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>All-cause mortality</measure>
    <time_frame>180 days</time_frame>
    <description>All-cause mortality at 180 days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HF re-hospitalization</measure>
    <time_frame>180 days</time_frame>
    <description>Re-hospitalization due to heart failure at 180 days</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">781</enrollment>
  <condition>Acute Heart Failure</condition>
  <arm_group>
    <arm_group_label>Standard of care</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Standard of care of acute decompensated heart failure will be according to the current guidelines of the European Society of Cardiology (ESC).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Intervention</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Early goal-directed preload and afterload decrement using a fixed therapy schedule including sublingual or nitrospray and transdermal nitrates together with hydralazine, followed by rapid up-titration of ACE-inhibitors , AT-receptor blockers or neprilysin inhibitors/AT-receptor blockers to achieve maximal vasodilatation with a target systolic blood pressure of 90-110 mmHg. All other elements of treatment will be according to the current guidelines of the European Society of Cardiology (ESC)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Goal-directed preload and afterload decrement</intervention_name>
    <description>Early goal-directed preload and afterload decrement with a target systolic blood pressure (RR) of 90-110 mmHg for the entire hospitalization using sublingual nitrates (Nitroglycerin Streuli®) or nitrospray (Corangin Nitrospray®) transdermal nitrates (Nitroderm TTS 10®), ACE-inhibitors (Triatec®) and/or ARB (Atacand®).</description>
    <arm_group_label>Intervention</arm_group_label>
    <other_name>Nitroglycerin Streuli®</other_name>
    <other_name>Nitroderm TTS 10®</other_name>
    <other_name>Triatec®</other_name>
    <other_name>Atacand®</other_name>
    <other_name>Corangin Nitrospray®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Acute HF expressed by acute dyspnea New York Heart Association (NYHA) class III or IV,&#xD;
             and a BNP-level ≥ 500 pg/ml. The diagnosis of acute HF is additionally based on&#xD;
             typical symptoms and clinical findings, supported by appropriate investigations such&#xD;
             as ECG, chest X-ray, and Doppler-echocardiography as recommended by current ESC&#xD;
             guidelines on the diagnosis and treatment of acute HF&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Cardiopulmonary resuscitation &lt; 7 days&#xD;
&#xD;
          -  Cardiogenic shock, ST-elevation myocardial infarction, or other clinical conditions&#xD;
             that require immediate ICU admission or urgent PTCA&#xD;
&#xD;
          -  Systolic blood pressure lower than 100 mmHg at presentation&#xD;
&#xD;
          -  Primary rhythmogenic cause of acute decompensation (ventricular tachycardia, reentry&#xD;
             tachycardia, atrial fibrillation or atrial flutter with a ventricular rate exceeding&#xD;
             140 beats per minute)&#xD;
&#xD;
          -  NSTEMI as primary diagnosis&#xD;
&#xD;
          -  Severe aortic stenosis&#xD;
&#xD;
          -  Adult congenital heart disease as primary cause of acute HF&#xD;
&#xD;
          -  Hypertrophic obstructive cardiomyopathy&#xD;
&#xD;
          -  Chronic kidney disease with creatinin levels &gt; 250 µmol/l&#xD;
&#xD;
          -  Bilateral renal artery stenosis&#xD;
&#xD;
          -  Severe sepsis or other causes of high output failure&#xD;
&#xD;
          -  Cirrhosis of the liver CHILD class C&#xD;
&#xD;
          -  Previous adverse reactions to nitrates&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christian Mueller, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Basel, Switzerland</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital Sao Paolo</name>
      <address>
        <city>São Paulo</city>
        <zip>04024-002</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>5-th Multifunctional Hospital for Active Treatment</name>
      <address>
        <city>Sofia</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Transport Hospital &quot;Tsar Boris III&quot;</name>
      <address>
        <city>Sofia</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital &quot;Tsaritsa Joanna-ISUL&quot;</name>
      <address>
        <city>Sofia</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Mainz</name>
      <address>
        <city>Mainz</city>
        <zip>55131</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nuremberg Hospital</name>
      <address>
        <city>Nuremberg</city>
        <zip>90419</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari Germans Trias i Pujol</name>
      <address>
        <city>Badalona</city>
        <zip>08916</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de la Santa Creu i Sant Pau</name>
      <address>
        <city>Barcelona</city>
        <zip>08041</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Basel</name>
      <address>
        <city>Basel</city>
        <state>BS</state>
        <zip>4031</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kantonsspital Aarau</name>
      <address>
        <city>Aarau</city>
        <zip>5001</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kantonsspital Luzern</name>
      <address>
        <city>Luzern</city>
        <zip>6000</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kantonsspital St. Gallen</name>
      <address>
        <city>St. Gallen</city>
        <zip>9007</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Brazil</country>
    <country>Bulgaria</country>
    <country>Germany</country>
    <country>Spain</country>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>August 6, 2007</study_first_submitted>
  <study_first_submitted_qc>August 7, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 8, 2007</study_first_posted>
  <last_update_submitted>November 20, 2019</last_update_submitted>
  <last_update_submitted_qc>November 20, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 21, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Hospital, Basel, Switzerland</investigator_affiliation>
    <investigator_full_name>Christian Müller, MD</investigator_full_name>
    <investigator_title>Prof. Dr. med.</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nitroglycerin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

